Novel Quinoline Compounds as EZH2 Inhibitors for Treating Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 West Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2022 Apr 13;13(5):755-756. doi: 10.1021/acsmedchemlett.2c00139. eCollection 2022 May 12.
Abstract
摘要
相似文献
1
Novel Quinoline Compounds as EZH2 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2022 Apr 13;13(5):755-756. doi: 10.1021/acsmedchemlett.2c00139. eCollection 2022 May 12.
2
Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2023 May 26;14(6):707-708. doi: 10.1021/acsmedchemlett.3c00195. eCollection 2023 Jun 8.
3
Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
J Comput Aided Mol Des. 2021 May;35(5):601-611. doi: 10.1007/s10822-021-00378-6. Epub 2021 Feb 26.
4
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
BMC Cancer. 2020 Dec 4;20(1):1189. doi: 10.1186/s12885-020-07667-7.
5
Cytotoxicity and cell cycle effects of novel indolo[2,3-b]quinoline derivatives.
Oncol Res. 2003;13(5):269-77. doi: 10.3727/096504003108748320.
6
5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors.
Molecules. 2015 Apr 27;20(5):7620-36. doi: 10.3390/molecules20057620.
7
Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
J Med Chem. 2023 Feb 23;66(4):2646-2662. doi: 10.1021/acs.jmedchem.2c01607. Epub 2023 Feb 12.
8
Targeting EZH2 for cancer therapy: From current progress to novel strategies.
Eur J Med Chem. 2022 Aug 5;238:114419. doi: 10.1016/j.ejmech.2022.114419. Epub 2022 Apr 30.
9
EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.
Front Immunol. 2022 Apr 1;13:857808. doi: 10.3389/fimmu.2022.857808. eCollection 2022.
10
Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Bioorg Med Chem Lett. 2017 Jan 15;27(2):217-222. doi: 10.1016/j.bmcl.2016.11.080. Epub 2016 Nov 25.
本文引用的文献
1
EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Biochim Biophys Acta Rev Cancer. 2022 Mar;1877(2):188700. doi: 10.1016/j.bbcan.2022.188700. Epub 2022 Feb 22.
2
New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer.
Cancer Commun (Lond). 2022 Feb;42(2):117-140. doi: 10.1002/cac2.12254. Epub 2022 Jan 12.
3
Non-coding RNAs-EZH2 regulatory mechanisms in cervical cancer: The current state of knowledge.
Biomed Pharmacother. 2022 Feb;146:112123. doi: 10.1016/j.biopha.2021.112123. Epub 2021 Dec 13.
4
Role of EZH2 in bone marrow mesenchymal stem cells and immune-cancer interactions.
Crit Rev Oncol Hematol. 2022 Jan;169:103547. doi: 10.1016/j.critrevonc.2021.103547. Epub 2021 Nov 26.
5
Critical role of the high mobility group A proteins in hematological malignancies.
Hematol Oncol. 2022 Feb;40(1):2-10. doi: 10.1002/hon.2934. Epub 2021 Oct 12.
6
Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models.
Cancer Sci. 2021 Aug;112(8):2948-2957. doi: 10.1111/cas.14990. Epub 2021 Jun 17.
Zotero 插件